Гипотензивная эффективность биматопроста в терапии первичной открытоугольной глаукомы


https://doi.org/10.25700/NJG.2019.01.11

Полный текст:


Аннотация

Глаукома — группа хронических заболеваний, ведущих к необратимой потере зрения. В выборе стратегии лечения глаукомы определяющими являются характер течения заболевания, факторы риска и темпы прогрессирования. Достижение «давления цели» способствует замедлению прогрессирования заболевания и повышению качества жизни пациентов. Эффективность, малая частота закапываний в сутки, а также отсутствие системных побочных эффектов являются важными факторами приверженности пациентов лечению. В арсенале врачей имеется несколько групп гипотензивных препаратов, каждая из которых обладает своими преимуществами и недостатками. В случае неэффективности стартовой монотерапии возможно назначение комбинации двух или даже трех гипотензивных препаратов. Чаще в качестве стартовой монотерапии назначают препараты группы аналогов простагландинов. Биматопрост, являясь простамидом, входит в эту группу, но отличается по фармакохимическим свойствам и эффективности от типичных простагландинов. Этот обзор посвящен опыту применения биматопроста, в частности, его фармакохимическим свойствам, эффективности и безопасности в сравнении с другими препаратами и комбинациями.


Об авторах

А. А. Антонов
ФГБНУ НИИ глазных болезней
Россия

Антонов Алексей Анатольевич - кандидат медицинских наук, ведущий научный сотрудник отдела глаукомы.

119021, Москва, ул. Россолимо, 11А



Т. М. Агаджанян
ФГБНУ НИИ глазных болезней
Россия

Аспирант.

119021, Москва, ул. Россолимо, 11А



А. А. Витков
ФГБНУ НИИ глазных болезней
Россия

Ординатор.

119021, Москва, ул. Россолимо, 11А



Список литературы

1. Нестеров А.П., Алексеев В.Н., Алексеев И.Б., Амиров А.Н., Астахов Ю.С., Балалин С.В. et al. Национальное руководство по глаукоме. Москва; 2015.

2. Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., Miller J.P. et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120(6):701-713; discussion 829-730.

3. Krauss A.H., Woodward D.F. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol. 2004; 49 Suppl 1:S5-11. doi: 10.1016/j.survophthal.2003.12.014.

4. Woodward D.F., Krauss A.H., Chen J., Liang Y., Li C., Protzman C.E., et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther. 2003; 305(2):772-785. doi: 10.1124/jpet.102.047837.

5. Christiansen G.A., Nau C.B., McLaren J.W., Johnson D.H. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology. 2004; 111(9):1658-1662. doi: 10.1016/j.ophtha.2004.02.006.

6. Woodward D.F., Krauss A.H., Chen J., Lai R.K., Spada C.S., Burk R.M. et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001; 45 Suppl 4:S337-345.

7. Richter M., Krauss A.H., Woodward D.F., Lutjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prosta-mide. Invest Ophthalmol Vis Sci. 2003; 44(10):4419-4426.

8. Liang Y., Li C., Guzman V.M., Evinger A.J., 3rd, Protzman C.E., Krauss A.H. et al. Comparison of prostaglandin F2alpha, bimato-prost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J Biol Chem. 2003; 278(29):27267-27277. doi: 10.1074/jbc.M301009200.

9. Laibovitz R.A., Van Denburgh A.M., Felix C., David R., Batoosingh A., Rosenthal A. et al. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol. 2001; 119(7):994-1000.

10. Toris C.B., Yablonski M.E., Wang Y.L., Hayashi M. Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat. Exp Eye Res. 1995; 61(6):649-657.

11. Simmons S.T., Bernstein P., Hollander D.A. A comparison of longterm intraocular pressure fluctuation in patients treated with bima-toprost or latanoprost. Am J Ophthalmol. 2008; 146(3):473-477. doi: 10.1016/j.ajo.2008.04.030.

12. Lawrence M.S., Miller J.W. Ocular tissue permeabilities. Int Ophthalmol Clin. 2004; 44(3):53-61.

13. Bhal S.K., Kassam K., Peirson I.G., Pearl G.M. The Rule of Five revisited: applying log D in place of log P in drug-likeness filters. Mol Pharm. 2007; 4(4):556-560. doi: 10.1021/mp0700209.

14. Schoenwald R.D., Deshpande G.S., Rethwisch D.G., Barfknecht C.F. Penetration into the anterior chamber via the conjunctival/scleral pathway. JOculPharmacol Ther. 1997; 13(1):41-59. doi:10.1089/jop.1997.13.41.

15. Ichhpujani P., Katz L.J., Hollo G., Shields C.L., Shields J.A., Marr B. et al. Comparison of human ocular distribution of bimatoprost and latanoprost. J Ocul Pharmacol Ther. 2012; 28(2):134-145. doi: 10.1089/jop.2011.0097.

16. Davies S.S., Ju W.K., Neufeld A.H., Abran D., Chemtob S., Roberts L.J., 2nd. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther. 2003; 19(1):45-54. doi: 10.1089/108076803762718105.

17. Cantor L.B., Hoop J., Wudunn D., Yung C.W., Catoira Y., Valluri S. et al. Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract. Br J Ophthalmol. 2007; 91(5):629-632. doi: 10.1136/bjo.2006.110155.

18. Sjoquist B., Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002; 47 Suppl 1:S6-12.

19. Sjoquist B., Johansson A., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Glaucoma Research Laboratories. Arzneimittelforschung. 1999; 49(3):240-249. doi: 10.1055/s-0031-1300408.

20. Sjoquist B., Tajallaei S., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye. Arzneimittelforschung. 1999; 49(3):225-233. doi: 10.1055/s-0031-1300406.

21. Sjoquist B., Uhlin A., Byding P., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye. Arzneimittelforschung. 1999; 49(3):234-239. doi: 10.1055/s-0031-1300407.

22. Cheng J.W., Wei R.L. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure. Clin Ther. 2008; 30(4):622-632.

23. Noecker R.S., Dirks M.S., Choplin N.T., Bernstein P., Batoosingh A.L., Whitcup S.M. et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003; 135(1):55-63.

24. Sawada A., Yamamoto T. Switching efficacy on intraocular pressure from latanoprost to bimatoprost in eyes with open angle glaucoma: implication to the changes of central corneal thickness. Jpn J Ophthalmol. 2014; 58(5):423-428. Doi :10.1007/s10384-014-0336-2.

25. Brennan N., Dehabadi M.H., Nair S., Quartilho A., Bunce C., Reekie I. et al. Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients. Int J Ophthalmol. 2017; 10(8):1251-1254. doi: 10.18240/ijo.2017.08.11.

26. DuBiner H., Cooke D., Dirks M., Stewart W.C., VanDenburgh A.M., Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001; 45 Suppl 4:S353-360.

27. Stalmans I., Oddone F., Cordeiro M.F., Hommer A., Montesano G., Ribeiro L. et al. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefes Arch Clin Exp Ophthalmol. 2016; 254(6):1151-1158. doi: 10.1007/s00417-016-3299-9.

28. Konstas A.G., Hollo G., Irkec M., Tsironi S., Durukan I., Goldenfeld M. et al. Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study. Br J Ophthalmol. 2007; 91(6):757-760. doi: 10.1136/bjo.2006.106690.

29. Lin L., Zhao Y.J., Chew P.T., Sng C.C., Wong H.T., Yip L.W. et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014; 48(12):1585-1593. doi: 10.1177/1060028014548569.

30. Aptel F., Cucherat M., Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008; 17(8):667-673. doi: 10.1097/IJG.0b013e3181666557.

31. Eisenberg D.L., Toris C.B., Camras C.B. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002; 47 Suppl 1:S105-115.

32. El Hajj Moussa W.G., Farhat R.G., Nehme J.C., Sahyoun M.A., Schakal A.R., Jalkh A.E. et al. Comparison of efficacy and ocular surface disease index score between bimatoprost, latanoprost, travoprost, and taflu-prost in glaucoma patients. J Ophthalmol. 2018; 2018:1319628. doi:10.1155/2018/1319628.

33. Parrish R.K., Palmberg P., Sheu W.P., Group X.L.T.S. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003; 135(5):688-703.

34. Maenpaa J., Pelkonen O. Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016; 15(11):1549-1561. doi: 10.1080/14740338.2016.1225718.

35. Nieminen T., Lehtimaki T., Maenpaa J., Ropo A., Uusitalo H., Kaho-nen M. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest. 2007; 67(2):237-245. doi: 10.1080/00365510601034736.

36. Oddone F., Rossetti L., Tanga L., Berardo F., Ferrazza M., Michelessi M. et al. Effects of topical bimatoprost 0.01% and timolol 0.5% on circadian iop, blood pressure and perfusion pressure in patients with glaucoma or ocular hypertension: a randomized, double masked, placebo-controlled clinical trial. PLoS One 2015; 10(10):e0140601. doi: 10.1371/journal.pone.0140601.

37. Higginbotham E.J., Schuman J.S., Goldberg I., Gross R.L., VanDen-burgh A.M., Chen K. et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002; 120(10):1286-1293.

38. Brandt J.D., VanDenburgh A.M., Chen K., Whitcup S.M., Bimatoprost Study G. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial. Ophthalmology. 2001; 108(6):1023-1031; discussion 1032.

39. Sherwood M., Brandt J., Bimatoprost Study G. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001; 45 Suppl 4:S361-368.

40. Vetrugno M., Cardascia N., Cantatore F., Sborgia C. Comparison of the effects of bimatoprost and timolol on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: A prospective, open-label, randomized, two-arm, parallel-group study. Curr Ther Res Clin Exp. 2004; 65(6):444-454. doi: 10.1016/j.curtheres.2005.01.004.

41. Cohen J.S., Gross R.L., Cheetham J.K., VanDenburgh A.M., Bernstein P., Whitcup S.M. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004; 49 Suppl 1:S45-52. doi: 10.1016/j.survoph-thal.2003.12.019

42. Olthoff C.M., Schouten J.S., van de Borne B.W., Webers C.A. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005; 112(6):953-961. doi: 10.1016/j.ophtha.2004.12.035.

43. Алексеев В.Н., Малеванная О.А., Тубаджи Е., Никитин Д.Н., Газизова И.Р. Прогрессирующая глаукома — неизбежность или недоработка? Национальный журнал глаукома. 2012; (3):26-31.

44. Taylor S.A., Galbraith S.M., Mills R.P. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther. 2002; 18(5):401-409. doi: 10.1089/10807680260362687.

45. Osman E.A., Alqarni B.A., AlHasani S.S., Al Harbi S.S., Gikandi P.W., Mousa A. Compliance of glaucoma patients to ocular hypotensive medications among the Saudi population. J Ocul Pharmacol Ther. 2016; 32(1):50-54. doi: 10.1089/jop.2015.0052.

46. Rajurkar K., Dubey S., Gupta P.P., John D., Chauhan L. Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India. J Curr Ophthalmol. 2018; 30(2):125-129. doi: 10.1016/j.joco.2017.09.002.

47. Roughead E.E., Kalisch L.M., Pratt N.L., Killer G., Barnard A., Gilbert A.L. Managing glaucoma in those with co-morbidity: not as easy as it seems. Ophthalmic Epidemiol. 2012; 19(2):74-82. doi: 10.3109/09286586.2011.638743

48. Maruyama Y., Ikeda Y., Mori K., Ueno M., Yoshikawa H., Kinoshita S. Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost. Clin Ophthalmol. 2015; 9:1429-1436. doi: 10.2147/OPTH.S87613.

49. Rossetti L., Sacchi M., Karabatsas C.H., Topouzis F., Vetrugno M., Centofanti M. et al. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood and ocular perfusion pressures: the results of a randomized trial. BMC Ophthalmol. 2015; 15:7. doi: 10.1186/1471-2415-15-7.

50. Facio A.C., Reis A.S., Vidal K.S., de Moraes C.G., Suzuki R., Hatanaka M. et al. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial. J Ocul Pharmacol Ther. 2009; 25(5):447-451. doi: 10.1089/jop.2009.0018.

51. Day D.G., Sharpe E.D., Beischel C.J., Jenkins J.N., Stewart J.A., Stewart W.C. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. Eur J Ophthalmol. 2005; 15(3):336-342.

52. Sharpe E.D., Williams R.D., Stewart J.A., Nelson L.A., Stewart W.C. A comparison of dorzolamide/timolol-fixed combination versus bima-toprost in patients with open-angle glaucoma who are poorly controlled on latanoprost. J Ocul Pharmacol Ther. 2008; 24(4):408-413. doi: 10.1089/jop.2008.0003


Дополнительные файлы

Для цитирования: Антонов А.А., Агаджанян Т.М., Витков А.А. Гипотензивная эффективность биматопроста в терапии первичной открытоугольной глаукомы. Национальный журнал глаукома. 2019;18(1):95-104. https://doi.org/10.25700/NJG.2019.01.11

For citation: Antonov A.A., Agadzhanyan T.M., Vitkov А.А. Hypotensive efficacy of bimatoprost in the treatment of primary open-angle glaucoma. National Journal glaucoma. 2019;18(1):95-104. (In Russ.) https://doi.org/10.25700/NJG.2019.01.11

Просмотров: 38

Обратные ссылки

  • Обратные ссылки не определены.


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2078-4104 (Print)
ISSN 2311-6862 (Online)